Under the new leadership of Marty Makary, the FDA should focus more attention on the critical role of real-world clinical data — such as from health insurance databases — in the ongoing assessment of ...

A new working paper has found that one-third of all data points collected in 105 phase 2 and 3 trials were not needed for the studies’ key analyses, while also highlighting how an increase in clinical ...